Medtronic (NYSE:MDT) today launched an outcomes-based reimbursement program for its MiniMed 670G automated insulin delivery system.
As part of its ‘MiniMed 670G Performance Guarantee Program,’ the medtech giant will dole out flat-fee reimbursements of up to $25,000 per pump over four years for diabetes-related inpatient hospitalization and ER admissions.
Get the full story at our sister site, Drug Delivery Business News.
The post Medtronic launches outcomes-based reimbursement program for MiniMed 670G system appeared first on MassDevice.